Research Search Results

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra

Status: Active, Recruiting

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Status: Active, Recruiting

De-intensified Radiation Therapy With Cisplatin or Nivolumab in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Status: Active, Recruiting

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Status: Active, Not Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Status: Active, Recruiting

Randomized Phase II/III Trial of Adjuvant Radiation Therapy (RT) with Cisplatin, Docetaxel Cetuximab, or Cisplatin Atezolizumab in Pathologic High Risk Squamous

Status: Active, Recruiting

Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Status: Active, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, lymphoma, and myeloma

Status: Active, Recruiting